Citius Announces Its Intention to Spin-Off I/ONTAK

Earlier today, Citius Pharmaceuticals issued a press release announcing its intention to spin-off its late stage oncology candidate, I/ONTAK, to a new, standalone publicly-traded company. In making the announcement, the company said that it believed that the market has not adequately valued the potential of its I/ONTAK licensing agreement.

Continue reading
Posted in CTXR, Health Care | Tagged | Leave a comment

DHC 22Q1 Update

22Q1 In Line with Expectations.  Maintaining Performance Rating and Price Target.

22Q1 GAAP earnings were $1.01 per share and normalized FFO $0.09 per share, in line with my expectations of $1.04 and $0.06.  Excluding a $327.8 million gain on the sale of JV interests, the performance of the Office Portfolio was moderately below expectations, but Senior Housing Operating Portfolio (SHOP) results were better than anticipated.

Continue reading
Posted in ALR, DHC, Real Estate | Tagged | Leave a comment

AlerisLife (ALR) 22Q1 Update

22Q1 Loss of $0.30 in Line with Expectations; Katie Potter Steps Down as CEO; ALR Hires Alvarez & Marsal to Conduct a Comprehensive Operational Review

AlerisLife reported a 22Q1 net loss of $9.7 million or $0.31 per diluted share, slightly better than its 21Q4 loss of $10.6 million or $0.34 per share.  I had estimated a $0.28 loss.

Continue reading
Posted in ALR, DHC, FVE, Health Care | Tagged | Leave a comment

GE 22Q1 Update

Since reporting disappoint 22Q1 results on April 26, GE’s stock has fallen sharply. Year-to-date, GE’s stock is down 22.6%, worse than the S&P 500 Industrial sector’s 11.7% decline.

Continue reading
Posted in GE, Industrials | Tagged , | Leave a comment

Citius Pharma 22Q1 Update

Citius Pharmaceuticals (CXTR) is a specialty pharmaceutical company focused on the development of five potential products: (1) Mino-Lok, an antibiotic lock solution to treat and salvage infected central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs); (2) I/ONTAK, a late-stage oncology immunotherapy for the treatment for cutaneous T-cell lymphoma (CTCL), that was acquired from Dr. Reddy’s Laboratories SA in September 2021; (3) Halo-Lido, a topical formation of halobetasol propionate and lidocaine for the treatment of hemorrhoids; (4) Mino-Wrap, a liquefying, gel-based wrap for the reduction of infections associated with breast implants following breast reconstructive surgeries; and (5) a next generation iPSC mesenchymal stem cell (iMSC) mRNA therapy, which is in pre-clinical development, under license from Brooklyn Immunotherapeutics (BTX).

Continue reading
Posted in CTXR, Health Care | Tagged | Comments Off on Citius Pharma 22Q1 Update

Mistras Group, Inc. (MG) 21Q4 Update

21Q4 Results Below Expectations, Lowering 2022 Estimates, Reducing Rating and Price Target

Mistras Group reported 21Q4 EPS of $0.00, slightly worse than 20Q4’s $0.01 and below my estimate of $0.06.  Revenues of $171.2 million were 6.5% above the year earlier period and better than I expected.  Despite the higher revenues, income from operations declined by 50% compared with the prior year.  Against my projections, Mistras’s revenues were higher, but operating costs were much higher.

Continue reading
Posted in Industrials, MG | Tagged | Comments Off on Mistras Group, Inc. (MG) 21Q4 Update

Thoughts on the Outlook for Homebuilding Stocks

Homebuilding stocks have had a rough 2022. Year-to-date (through 4/12), my equal-weighted index of 11 publicly-traded U.S. homebuilders has fallen 34.8%. That compares with declines of 7.7% in the S&P 500 and 11.5% in the Russell 2000.

Following a three-fold surge in the index from the March 2020 lows to the May 2021 highs, homebuilding stocks were due for a correction anyway. This year’s 34% fall, though eye-catching, still qualifies as a normal correction from a technical point of view, according to Fibonacci retracement analysis.

Continue reading
Posted in BZH, Consumer Discretionary, Housing, KBH, TOL | Tagged , | Comments Off on Thoughts on the Outlook for Homebuilding Stocks

Going to Neutral on Big Pharma

The stocks of large pharmaceutical companies, including Bristol-Myers Squibb (BMY) and Merck & Co. (MRK), which I follow, have outperformed the market significantly so far this year. The pharmaceuticals sector, as measured by the NYSE Arca Pharmaceuticals Index ($DRG) shows a year-to-date gain of 5.2%, as of this post, much better than the S&P 500’s 6.5% decline.

Continue reading
Posted in Uncategorized | Comments Off on Going to Neutral on Big Pharma

AlerisLife (ALR) 21Q4 Update

Lowering Estimates and Safety Rating, Withdrawing Performance Rating and Price Target

AlerisLife Inc. (ALR), formerly known as Five Star Senior Living, reported a fourth quarter net loss of $10.7 million or $0.34 per share, slightly worse than the third quarter’s loss of $10.2 million or $0.32 per share.  I had estimated a $0.15 loss.

Continue reading
Posted in ALR, DHC, FVE, Health Care | Tagged , | Comments Off on AlerisLife (ALR) 21Q4 Update

Toll Brothers (TOL) 22Q1 Update

Since my last report on December 9, 2021, Toll’s stock has fallen 26.3%, much more than the S&P Mid-Cap 400’s 2.6% decline.  As I noted back then, shares of Toll and other homebuilders were ripe for a correction following their three-fold advance off the early pandemic lows.  Yet, this correction has been more severe than I had anticipated, driven by persistent inflation, rising mortgage rates and most recently the uncertainty of the economic fallout from Ukraine.

Continue reading
Posted in Consumer Discretionary, Housing, TOL | Tagged | Comments Off on Toll Brothers (TOL) 22Q1 Update